JP2025510916A5 - - Google Patents
Info
- Publication number
- JP2025510916A5 JP2025510916A5 JP2024557205A JP2024557205A JP2025510916A5 JP 2025510916 A5 JP2025510916 A5 JP 2025510916A5 JP 2024557205 A JP2024557205 A JP 2024557205A JP 2024557205 A JP2024557205 A JP 2024557205A JP 2025510916 A5 JP2025510916 A5 JP 2025510916A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disorder
- dose
- dmt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22000083.0 | 2022-03-27 | ||
| EP22000086 | 2022-03-27 | ||
| EP22000086.3 | 2022-03-27 | ||
| EP22000083 | 2022-03-27 | ||
| EP23153995.8 | 2023-01-30 | ||
| EP23153939 | 2023-01-30 | ||
| EP23153995 | 2023-01-30 | ||
| EP23153939.6 | 2023-01-30 | ||
| PCT/EP2023/057877 WO2023186830A1 (en) | 2022-03-27 | 2023-03-27 | 5-methoxy-n,n-dimethyltryptamine for the treatment of psychomotor retardation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510916A JP2025510916A (ja) | 2025-04-15 |
| JP2025510916A5 true JP2025510916A5 (enExample) | 2026-04-10 |
Family
ID=86007166
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557191A Pending JP2025510912A (ja) | 2022-03-27 | 2023-03-27 | 双極性障害を処置するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557759A Pending JP2025510369A (ja) | 2022-03-27 | 2023-03-27 | 社会的／情動的引きこもりまたは離隔の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557755A Pending JP2025511081A (ja) | 2022-03-27 | 2023-03-27 | 睡眠障害の治療における使用のための５－ＭｅＯ－ＤＭＴ |
| JP2024557758A Pending JP2025510368A (ja) | 2022-03-27 | 2023-03-27 | 不安の処置 |
| JP2024557205A Pending JP2025510916A (ja) | 2022-03-27 | 2023-03-27 | 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557204A Pending JP2025512831A (ja) | 2022-03-27 | 2023-03-27 | 認知機能障害の治療 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557191A Pending JP2025510912A (ja) | 2022-03-27 | 2023-03-27 | 双極性障害を処置するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557759A Pending JP2025510369A (ja) | 2022-03-27 | 2023-03-27 | 社会的／情動的引きこもりまたは離隔の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557755A Pending JP2025511081A (ja) | 2022-03-27 | 2023-03-27 | 睡眠障害の治療における使用のための５－ＭｅＯ－ＤＭＴ |
| JP2024557758A Pending JP2025510368A (ja) | 2022-03-27 | 2023-03-27 | 不安の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557204A Pending JP2025512831A (ja) | 2022-03-27 | 2023-03-27 | 認知機能障害の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (9) | US20250241893A1 (enExample) |
| EP (7) | EP4499088A1 (enExample) |
| JP (6) | JP2025510912A (enExample) |
| KR (6) | KR20250005183A (enExample) |
| CN (2) | CN119095595A (enExample) |
| AU (6) | AU2023246774A1 (enExample) |
| CA (6) | CA3255348A1 (enExample) |
| IL (6) | IL315899A (enExample) |
| WO (9) | WO2023186820A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| EP4155306A1 (en) | 2021-01-15 | 2023-03-29 | Beckley Psytech Limited | Neuroactive ergoline analogue |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202306256D0 (en) * | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026078143A1 (en) | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19803376C1 (de) | 1998-01-29 | 1999-10-14 | Markus Storz | Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten |
| US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US20040234916A1 (en) | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| ES2355983T3 (es) | 2006-08-01 | 2011-04-01 | STOBI GMBH & CO. KG | Balón de válvula para inhaladores . |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| HUE069534T2 (hu) * | 2019-02-22 | 2025-03-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra |
| US12377112B2 (en) * | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| EP3868364A1 (en) * | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| WO2021216489A1 (en) * | 2020-04-20 | 2021-10-28 | Lobe Sciences Ltd. | Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury |
| BR112022025306A2 (pt) * | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| US11406619B2 (en) * | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US20240299353A1 (en) | 2021-03-12 | 2024-09-12 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
-
2023
- 2023-03-27 IL IL315899A patent/IL315899A/en unknown
- 2023-03-27 CA CA3255348A patent/CA3255348A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057867 patent/WO2023186820A1/en not_active Ceased
- 2023-03-27 EP EP23717412.3A patent/EP4499088A1/en active Pending
- 2023-03-27 CA CA3255340A patent/CA3255340A1/en active Pending
- 2023-03-27 KR KR1020247035762A patent/KR20250005183A/ko active Pending
- 2023-03-27 US US18/850,376 patent/US20250241893A1/en active Pending
- 2023-03-27 AU AU2023246774A patent/AU2023246774A1/en active Pending
- 2023-03-27 KR KR1020247035758A patent/KR20250005181A/ko active Pending
- 2023-03-27 IL IL315902A patent/IL315902A/en unknown
- 2023-03-27 WO PCT/EP2023/057870 patent/WO2023186823A1/en not_active Ceased
- 2023-03-27 EP EP23717035.2A patent/EP4499075A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057857 patent/WO2023186816A1/en not_active Ceased
- 2023-03-27 AU AU2023242291A patent/AU2023242291A1/en active Pending
- 2023-03-27 IL IL315898A patent/IL315898A/en unknown
- 2023-03-27 IL IL315891A patent/IL315891A/en unknown
- 2023-03-27 KR KR1020247035718A patent/KR20250005176A/ko active Pending
- 2023-03-27 EP EP23717036.0A patent/EP4499076A1/en not_active Withdrawn
- 2023-03-27 WO PCT/EP2023/057842 patent/WO2023186806A1/en not_active Ceased
- 2023-03-27 CA CA3255505A patent/CA3255505A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057877 patent/WO2023186830A1/en not_active Ceased
- 2023-03-27 US US18/851,346 patent/US20250241895A1/en active Pending
- 2023-03-27 CA CA3255629A patent/CA3255629A1/en active Pending
- 2023-03-27 KR KR1020247035659A patent/KR20240167879A/ko active Pending
- 2023-03-27 EP EP23717033.7A patent/EP4499073A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057883 patent/WO2023186835A1/en not_active Ceased
- 2023-03-27 JP JP2024557191A patent/JP2025510912A/ja active Pending
- 2023-03-27 JP JP2024557759A patent/JP2025510369A/ja active Pending
- 2023-03-27 AU AU2023246543A patent/AU2023246543A1/en active Pending
- 2023-03-27 EP EP23717042.8A patent/EP4499082A1/en active Pending
- 2023-03-27 US US18/850,383 patent/US20250205256A1/en not_active Abandoned
- 2023-03-27 JP JP2024557755A patent/JP2025511081A/ja active Pending
- 2023-03-27 JP JP2024557758A patent/JP2025510368A/ja active Pending
- 2023-03-27 US US18/850,362 patent/US20250241892A1/en active Pending
- 2023-03-27 CN CN202380030914.XA patent/CN119095595A/zh active Pending
- 2023-03-27 IL IL315897A patent/IL315897A/en unknown
- 2023-03-27 IL IL315896A patent/IL315896A/en unknown
- 2023-03-27 WO PCT/EP2023/057876 patent/WO2023186829A1/en not_active Ceased
- 2023-03-27 CA CA3255343A patent/CA3255343A1/en active Pending
- 2023-03-27 CA CA3255648A patent/CA3255648A1/en active Pending
- 2023-03-27 AU AU2023244452A patent/AU2023244452A1/en active Pending
- 2023-03-27 KR KR1020247035746A patent/KR20250005179A/ko active Pending
- 2023-03-27 JP JP2024557205A patent/JP2025510916A/ja active Pending
- 2023-03-27 US US18/850,348 patent/US20250241891A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057827 patent/WO2023186797A1/en not_active Ceased
- 2023-03-27 EP EP23717031.1A patent/EP4499226A1/en active Pending
- 2023-03-27 EP EP23717043.6A patent/EP4499083A1/en active Pending
- 2023-03-27 US US18/851,343 patent/US20250213532A1/en active Pending
- 2023-03-27 AU AU2023246545A patent/AU2023246545A1/en active Pending
- 2023-03-27 US US18/850,370 patent/US20250205199A1/en active Pending
- 2023-03-27 AU AU2023246679A patent/AU2023246679A1/en active Pending
- 2023-03-27 KR KR1020247035653A patent/KR20250005170A/ko active Pending
- 2023-03-27 WO PCT/EP2023/057873 patent/WO2023186826A1/en not_active Ceased
- 2023-03-27 JP JP2024557204A patent/JP2025512831A/ja active Pending
- 2023-03-27 CN CN202380031464.6A patent/CN119053327A/zh active Pending
- 2023-09-27 US US18/373,903 patent/US20240108601A1/en active Pending
- 2023-09-27 US US18/373,906 patent/US20240108602A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025510916A5 (enExample) | ||
| JP2025510294A5 (enExample) | ||
| US20240382436A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| JP2025510369A5 (enExample) | ||
| JP2025510368A5 (enExample) | ||
| US6335021B1 (en) | Composition for controlling mood disorders in healthy individuals | |
| JP2025510295A5 (enExample) | ||
| JP2025512831A5 (enExample) | ||
| JP2025511081A5 (enExample) | ||
| Lapid et al. | Efficacy, safety, and tolerability of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies: a pilot study | |
| JP2025511084A5 (enExample) | ||
| JP2025510912A5 (enExample) | ||
| JP2025510913A5 (enExample) | ||
| JP2025510914A5 (enExample) | ||
| JP2025510296A5 (enExample) | ||
| EP3813816B1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome | |
| JP2022521233A5 (enExample) | ||
| KR20180034442A (ko) | 아캄프로세이트와 d-사이클로세린을 사용한 병용 치료 | |
| CN103156876B (zh) | 一种治疗中枢神经系统疾病的药物组合物及其制备方法和用途 | |
| TW201320994A (zh) | 投藥療程 | |
| JP2022536331A (ja) | シヌクレイノパチーの治療 | |
| JP2019504040A (ja) | 中等度〜重度のインフルエンザの処置 | |
| JP2021530568A5 (enExample) | ||
| JP2025511072A5 (enExample) | ||
| US12514842B2 (en) | Use of a benzoate containing composition to treat neurodegenerative disorders |